Stock 301258 SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Suzhou Fushilai Pharmaceutical Co., Ltd.

Equities

301258

CNE1000058W2

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
29.9 CNY +0.57% Intraday chart for Suzhou Fushilai Pharmaceutical Co., Ltd. -3.98% -7.37%
Apr. 22 Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 01 Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI

Business Summary

Suzhou Fushilai Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and raw materials for health care products. The Company's main products include three series of lipoic acid series, phosphatidylcholine series and carnosine series. The Company mainly conducts its business in domestic and overseas markets such as Europe, America, Japan and South Korea, India and South America.

Number of employees: 544

Sales per Business

CNY in Million2022Weight2023Weight Delta
Lipoic Acid Series
76.6 %
454 79.9 % 375 76.6 % -17.38%
Carnosine Series
12.2 %
53 9.3 % 60 12.2 % +13.56%
Phosphatidylcholine Series
8.5 %
40 7.1 % 42 8.5 % +2.91%
Irecoxib
1.4 %
2 0.4 % 7 1.4 % +231.99%
Other Business
1.3 %
19 3.4 % 6 1.3 % -67.86%

Sales per region

CNY in Million2022Weight2023Weight Delta
Abroad
62.9 %
371 65.2 % 308 62.9 % -16.93%
China
37.1 %
198 34.8 % 181 37.1 % -8.19%

Managers

Managers TitleAgeSince
Xiang Yun Qian CEO
 Chief Executive Officer 54 00-10-31
Yi Qian CHM
 Chairman 49 10-02-28
Ai Jin Bian DFI
 Director of Finance/CFO 38 14-02-28
Jian Gang Lu BRD
 Director/Board Member 44 99-12-31

Members of the board

Members of the board TitleAgeSince
Ying Xian Shen BRD
 Director/Board Member 38 19-09-11
Jia Sheng Tu BRD
 Director/Board Member 60 22-09-08
Zhong Chen BRD
 Director/Board Member 61 22-09-08
Xiang Yun Qian CEO
 Chief Executive Officer 54 00-10-31
Ai Jin Bian DFI
 Director of Finance/CFO 38 14-02-28
Jian Gang Lu BRD
 Director/Board Member 44 99-12-31
Yi Qian CHM
 Chairman 49 10-02-28

Shareholders

NameEquities%Valuation
Galaxy Asset Management Co., Ltd.
-
866,350 - 3 M ¥
Everbright PGIM Fund Management Co. Ltd.
-
251,342 - 976 700 ¥
China Southern Asset Management Co., Ltd.
-
155,900 - 605 818 ¥
Golden Trust Sinopac Fund Management Co., Ltd.
-
99,100 - 385 097 ¥
Hui'an Fund Management Co. Ltd.
-
60,700 - 235 877 ¥
Hongde Fund Management Co., Ltd.
-
15,900 - 61 786 ¥
HFT Investment Management Co., Ltd.
-
14,600 - 56 735 ¥
Citic Securities Co., Ltd. (Invt Port)
-
12,900 - 50 129 ¥
Da Cheng Fund Management Co., Ltd.
-
2,726 - 10 593 ¥
Fortune & Royal Asset Management Co., Ltd.
-
2,206 - 8 572 ¥

Company contact information

Suzhou Fushilai Pharmaceutical Co., Ltd.

16 Haiwang Road New Materials Industrial Park

215500, Changshu

+

http://www.fuslai.com
address Suzhou Fushilai Pharmaceutical Co., Ltd.(301258)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD. Stock Suzhou Fushilai Pharmaceutical Co., Ltd.
-7.37% 378M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301258 Stock
  4. Company Suzhou Fushilai Pharmaceutical Co., Ltd.